Alzheimer's disease and related dementias have multiple causative factors that lead to signaling imbalances, loss of cell function, and ultimately neurodegeneration. Abnormal protein phosphorylation is a critical signaling imbalance resulting from the inappropriate activities of kinases and phosphatases. While drug discovery and development efforts have focused exclusively on inhibiting kinases, the activation of phosphatases remains an unexplored, yet promising strategy to restore normal protein phosphorylation. Signum Biosciences' lead drug candidate, SIG1012, elevates the activity of the major brain phosphatase, PP2A. Further development of SIG1012 and related compounds, offers a novel approach to restoring healthy protein phosphorylation.